Floatz logo

Doxepin

Esophageal Carcinoma

Mayo ClinicSmall moleculePhase 2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

41 Active assets in the Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
Capivasertib
National Cancer Institute (NCI)
Phase 2CCC
Thalidomide
Henan Cancer Hospital
Phase 2CCC

View all 50 →

Same molecule, other indications

Doxepin is also rated in:

depressive disorderDormant
CC
Indicative ·
43 / 100
View asset →
dementiaDormant
CC
Indicative ·
43 / 100
View asset →
physiological malfunction arising from mental factorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →